Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00…
News
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients…
Sernova Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™ at American Diabetes Association 83rd Scientific Sessions
In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients…
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
POINT’s vertically integrated platform together with AdvanCell’s lead-212 (²¹²Pb) generator technology enables both the development…
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification…
POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress
Auger electron and beta emitting isotope terbium-161 was paired with POINT’s FAP-targeted PNT6555 ligand and…
Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease
FLT201 is a highly differentiated AAV gene therapy candidate that delivers a longer-acting engineered variant…
Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical…
Syneos Health and uMotif Partner to Deliver Patient-centric eClinical Platform
Integrated eCOA & ePRO Solution Taps Company’s Decentralized Capabilities and Technology Expertise MORRISVILLE, N.C., June 26,…
Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary SEDDS Technology Capsules for Canadian and International markets
Avicanna and Medipharm Labs Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary…
CarGurus Further Enhances Automotive Search and Shopping with Introduction of ChatGPT Plugin
The most visited automotive shopping site in the U.S.¹ builds on its artificial intelligence (AI)…
Grom’s Curiosity Ink Media and Dynamite Entertainment Bring Four Children’s Titles to Booksellers Everywhere in Time for the Holidays!
Curiosity Ink Media and Dynamite Publishing Team Up for Four Holiday Books for Kids Curiosity…
ProvisionAI Helps Kimberly-Clark Win the Innovation Award at Kinexions 2023
Combination of Kinaxis Rapid Response and ProvisionAI’s LevelLoad Has Been a Real Game-Changer for Kimberly-Clark,…
Impero Software Adds AI, Machine Learning to Holistic Classroom Tool for Student Safety
“Wellbeing” Tool Will Incorporate AI to Scan for Warning Flags of Mental Health or Physical…
Intermap Announces Subscription with Outdoor Recreation Platform
Integration of high-resolution elevation data enhances outdoor mapping experience DENVER, June 26, 2023 (GLOBE NEWSWIRE)…
Personas Update on Re-Launch of Keek
Toronto, Ontario–(Newsfile Corp. – June 26, 2023) – Personas Social Incorporated (TSXV: PRSN) (the “Company“) is pleased…
Hypercharge Announces Partnership with Precise ParkLink
Vancouver, British Columbia and Toronto, Ontario–(Newsfile Corp. – June 26, 2023) – Hypercharge Networks Corp….
Micromem Progress Report on Romanian Projects
Toronto, Ontario and New York, New York–(Newsfile Corp. – June 26, 2023) – Micromem Technologies…
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
PEARL RIVER, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has received notification…
Twist Bioscience Publishes Preclinical Data in Diabetes Validating GLP-1R Antagonist Antibody as Potential Treatment for Congenital Hyperinsulinism
— TB-222-023 Discovered and Optimized Using Twist’s Synthetic DNA Libraries and Antibody Engineering Services —…